• LAST PRICE
    16.5300
  • TODAY'S CHANGE (%)
    Trending Up0.4100 (2.5434%)
  • Bid / Lots
    16.2000/ 4
  • Ask / Lots
    16.5200/ 1
  • Open / Previous Close
    16.3200 / 16.1200
  • Day Range
    Low 16.3200
    High 16.5300
  • 52 Week Range
    Low 12.9500
    High 25.4700
  • Volume
    5,123
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 16.12
TimeVolumeRCUS
09:32 ET476616.53
09:34 ET20016.53
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRCUS
Arcus Biosciences Inc
1.5B
-5.3x
---
United StatesARDX
Ardelyx Inc
1.6B
-23.9x
---
United StatesVIR
Vir Biotechnology Inc
1.4B
-2.7x
---
United StatesXNCR
Xencor Inc
1.5B
-11.0x
---
United StatesGYRE
Gyre Therapeutics Inc
1.0B
-6.4x
---
United StatesIMTX
Immatics NV
1.2B
-10.9x
---
As of 2024-05-28

Company Information

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Contact Information

Headquarters
3928 Point Eden WayHAYWARD, CA, United States 94545-3719
Phone
510-694-6200
Fax
302-730-1370

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder
Terry Rosen
President, Co-Founder
Juan Jaen
Chief Financial Officer
Robert Goeltz
Chief Operating Officer
Jennifer Jarrett
General Counsel
Carolyn Tang

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.5B
Revenue (TTM)
$237.0M
Shares Outstanding
91.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.86
EPS
$-3.10
Book Value
$6.12
P/E Ratio
-5.3x
Price/Sales (TTM)
6.2
Price/Cash Flow (TTM)
---
Operating Margin
-113.92%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.